Abstracts Archive - Page 2207 of 2607 - ACR Meeting Abstracts

Abstract Number: 384 • 2014 ACR/ARHP Annual Meeting
Using Patient Reported Outcome Measures to Classify Disease Activity States in Rheumatoid Arthritis: A Comparison of Patient Activity Score (PAS) and Routine Assessment of Patient Index Data (RAPID)
Erin Carruthers¹, Noura AL Osaimi², Charles H Goldsmith³, Paul Adam⁴ and Diane Lacaille⁵, ¹Arthritis Research Centre of Canada, Richmond, BC, Canada, ²Rheumatology, University of Ottawa, Ottawa, ON, Canada, ³Health Sciences, Simon Fraser University, Burnaby, BC, Canada, ⁴Mary Pack Arthritis Centre, Vancouver, BC, Canada, ⁵Arthritis Research Centre of Canada, Vancouver, BC, Canada
Background/PurposeIn RA the target for treatment is clinical remission or minimal disease activity. Patient involvement in monitoring their disease activity could enhance treatment by providing…
Abstract Number: 382 • 2014 ACR/ARHP Annual Meeting
What Is More Predictive of Achieving Remission at 12 Months: The Percentage of Baseline Improvement or the Actual Disease State Achieved at 6 Months?
Edward C. Keystone¹, Carter Thorne², Michael Starr³, Jude Rodrigues⁴, Philip Baer⁵, Regan Arendse⁶, J. Antonio Avina-Zubieta⁷, Denis Choquette⁸, Emmanouil Rampakakis⁹, John S. Sampalis⁹, May Shawi¹⁰, Francois Nantel¹⁰, Allen J Lehman¹¹ and Susan Otawa¹¹, ¹Medicine, University of Toronto, Toronto, ON, Canada, ²Southlake Regional Health Centre, Newmarket, ON, Canada, ³Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ⁴Clinical Research and Arthritis Centre, Windsor, ON, Canada, ⁵Private Practice, Scarborough, ON, Canada, ⁶University of Saskatchewan, Saskatoon, SK, Canada, ⁷Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁸Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ⁹JSS Medical Research, Montreal, QC, Canada, ¹⁰Janssen Inc., Toronto, ON, Canada, ¹¹Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: The aim of rheumatoid arthritis (RA) treatment is to optimize symptom control and, when possible, achieve sustained remission. Therefore, identification of clinical signs predicting…
Abstract Number: 381 • 2014 ACR/ARHP Annual Meeting
Distribution and Clinical Significance of Anti-Heterogenic Nuclear Ribonucleoprotein A2 Antibody in Connective Tissue Diseases
Wang Yong Sr.¹, Mu Fangxiang¹, Wu Hong² and Fang Yongfei², ¹Department of Rheumatology,, Southwest Hospital, Third Military Medical University, Chongqing, China, ²Department of Rheumatology, Southwest Hospital, Third Military Medical University, Chongqing, China
Distribution and clinical significance of anti-heterogeneous nuclear ribonucleoprotein A2 antibody in connective tissue diseasesAbstract: Background/Purpose:The heterogeneous nuclear ribonucleoprotein A2 (hnRNP-A2) has been described as an…
Abstract Number: 379 • 2014 ACR/ARHP Annual Meeting
What Level of Disease Activity at 6 Months Predicts Achieving or Sustaining Remission at 12 Months?
Edward Keystone¹, Philip Baer², Boulos Haraoui³, J Antonio Avina-Zubieta⁴, Andrew Chow⁵, Dalton Sholter⁶, Denis Choquette⁷, Emmanouil Rampakakis⁸, John S. Sampalis⁸, Francois Nantel⁹, Allen J Lehman¹⁰, May Shawi⁹ and Susan Otawa¹⁰, ¹Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ²Private Practice, Scarborough, ON, Canada, ³University of Montreal Hospital Centre, Montreal, QC, Canada, ⁴Experimental Medicine, University of British Columbia, Department of Experimental Medicine, Vancouver, BC, Canada, ⁵McMaster University, Hamilton and Credit Valley Hospital, Mississauga, ON, Canada, ⁶University of Alberta, Edmonton, AB, Canada, ⁷Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ⁸JSS Medical Research, Montreal, QC, Canada, ⁹Janssen Inc., Toronto, ON, Canada, ¹⁰Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Achievement of clinical remission in rheumatoid arthritis (RA) is a process that may take several months. Identification of clinical signs predicting future remission may…
Abstract Number: 398 • 2014 ACR/ARHP Annual Meeting
Anti-Rheumatic Therapy Decreases Syndecan-1 Shedding in Rheumatoid Arthritis (RA)
Ivana Hollan¹, Gunnbjørg Hjeltnes², Torstein Lyberg³, Stefan Agewall³, Allan Wiik⁴, Knut Mikkelsen⁵, Øystein T. Førre⁶, Tram T. Vuong³ and Svein O. Kolset³, ¹Rheumatology, Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, ²Medicine, Innlandet Hospital Trust, Lillehammer, Norway, ³University of Oslo, Oslo, Norway, ⁴Clinical Biochem/Immunology, Statens Serum Institute, Copenhagen S, Denmark, ⁵Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, ⁶Oslo University Hospital, Oslo, Norway
Background/Purpose Intact glycocalyx is of importance for healthy endothelial function. Changes in the endothelial glycocalyx, characterized by increased levels of circulating syndecan-1, might be related…
Abstract Number: 397 • 2014 ACR/ARHP Annual Meeting
Th9 Lymphocytes in Rheumatoid Arthritis
Rossella Talotta¹, Angela Berzi², Fabiola Atzeni¹, Donata Dell'Acqua¹, Piercarlo Sarzi-Puttini¹ and Daria Trabattoni², ¹Rheumatology Unit, L. Sacco University Hospital, Milan, Italy, ²Chair of Immunology, Department of Biomedical and Clinical Sciences “L. Sacco, Milan, Italy
Background/Purpose Th9 cells are IL-9-secreting Th lymphocytes that are involved in the immunological responses underlying parasitic infections and allergic diseases. In the case of autoimmune…
Abstract Number: 396 • 2014 ACR/ARHP Annual Meeting
Disease Activity Scoring: Comparing Patient and Physician Global Assessment of Disease Activity in Rheumatoid Arthritis
Boulos Haraoui¹, Denis Choquette¹, Jean-Pierre Raynauld¹, Jean Pierre Pelletier¹, Louis Bessette², Edith Villeneuve¹, Marie-Anaïs Rémillard³, Isabelle Fortin⁴, Diane Sauvageau¹ and Louis Coupal¹, ¹Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ²Rheumatology, Centre d’ostéoporose et de rhumatologie de Québec (CORQ), Québec, QC, Canada, ³Rhumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ⁴Centre de rhumatologie de l'est du Québec (CREQ), Rimouski, QC, Canada
Background/Purpose: Visual analogue scales (VAS) are routinely used in daily clinical practice and are part of the different composite outcome measures. Studies often report weak…
Abstract Number: 395 • 2014 ACR/ARHP Annual Meeting
Could Osteoprotegerin and TNF-Related Apoptosis-Inducing Ligand Assessments Help Us to Manage Early Rheumatoid Arthritis? Results from the Espoir Cohort
Rachel Audo¹, Claire I. Daien², Laura Papon¹, Cédric Lukas³, O Vittecoq⁴, B Combe⁵ and Jacques Morel⁶, ¹IGMM, CNRS UMR5535, Montpellier, Montpellier, France, ²Department of Rheumatology, Lapeyronie Hospital, Montpellier, France, ³Immuno-Rhumatologie, Hopital Lapeyronie, Montpellier, France, ⁴Rouen University Hospital & Inserm U905, Rouen, France, ⁵Immuno-Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ⁶Department of Rheumatology, Hôpital Lapeyronie, Montpellier, France
Background/Purpose : TNF-Related Apoptosis Inducing Ligand (TRAIL) is a member of the TNF familly. Its soluble receptor Osteoprotegerin (OPG) also inhibits Receptor activator of nuclear…
Abstract Number: 394 • 2014 ACR/ARHP Annual Meeting
Very Low or High Body Mass Index Negatively Affects patients’ Ability to Achieve Sustained Remission in Early RA in a Multicenter Canadian Cohort
Susan M. Goodman¹, Yan Ma², Wei Zhang³, Elizabeth Schulman⁴, Janet E. Pope⁵, Carol Hitchon⁶, Susan J. Bartlett⁷, Boulos Haraoui⁸, Daming Lin⁹, Gilles Boire¹⁰, Diane Tin¹¹, J. Carter Thorne¹², Shahin Jamal¹³, Edward C. Keystone¹⁴ and Vivian P. Bykerk^1,15, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Research - Epidemiology and Biostatistics, Hospital for Special Surgery, New York, NY, ³Healthcare Research Institute, Hospital for Special Surgery, New York, NY, ⁴Rheumatology, New York Presbyterian - Cornell Campus - HSS, New York, NY, ⁵St Joseph Health Care, London, ON, Canada, ⁶Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ⁷Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ⁸University of Montreal Hospital Centre, Montreal, QC, Canada, ⁹Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ¹⁰Rheumatology Division, CHUS - Sherbrooke University, Sherbrooke, QC, Canada, ¹¹The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²Southlake Regional Health Centre, Newmarket, Newmarket, ON, Canada, ¹³Vancouver General Hospital, Vancouver, BC, Canada, ¹⁴Medicine, University of Toronto, Toronto, ON, Canada, ¹⁵Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose: To determine if patients with a very low body mass index (BMI) (
Abstract Number: 393 • 2014 ACR/ARHP Annual Meeting
Influence of Body Mass Index on Disease Activity and Radiographic Joint Damage in Rheumatoid Arthritis : A Systematic Review and Meta-Analysis
Celine Vidal¹, Thomas Barnetche², Jacques Morel³, Bernard Combe⁴ and Claire Daien⁵, ¹Rheumatology, Hopital Lapeyronie, Montpellier, France, ²rheumatology, Rheumatology department, Bordeaux University Hospital, bordeaux, France, ³Department of Rheumatology, Hôpital Lapeyronie, Montpellier, France, ⁴Immuno-Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ⁵Hopital Lapeyronie, Montpellier, France
Background/Purpose: Overweight and obesity in patients with rheumatoid arthritis (RA) are rising conditions. Adipose tissue has pro inflammatory properties by producing adipokines which could play…
Abstract Number: 392 • 2014 ACR/ARHP Annual Meeting
Neuroendocrine Hormone and Metabolic Peptide Levels in the Earliest Phases of Rheumatoid Arthritis – Do Free Fatty Acids Play a Role?
Man Wai Tang¹, Frieda A. Koopman², Jan P.M. Visscher², Marjolein J.H. de Hair², Danielle M. Gerlag^2,3 and Paul P. Tak^2,4, ¹Division of Clinical Immunology and Rheumatology & Department of Experimental Immunology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ²Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ³GlaxoSmithKline, Cambridge, United Kingdom, ⁴University of Cambridge, Cambridge and GlaxoSmithKline, Stevenage, United Kingdom
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease associated with several neuroendocrine hormones and metabolic peptides. The crosstalk between the hormones and the immune…
Abstract Number: 391 • 2014 ACR/ARHP Annual Meeting
Self-Assessment Tool of Rheumatoid Arthritis Disease Activity: Handgrip Strength Measured By a Smartphone Connected to a Dynamometer
Francisco Espinoza Sr.¹, Yves-marie Pers Sr.², Pierre LeBlay Sr.² and Christian Jorgensen², ¹Rheumatology Department, Division of Internal Medicine, School of Medicine, University of Los Andes, Santiago, Chile, ²Clinical Immunology and Osteoarticular Diseases Therapeutic Unit, CHU Lapeyronie., Montpellier, France
Background/Purpose Patient self-management should become a key component of rheumatology care. Development of modalities using personal technologies resources represents an attractive way to assess periodic…
Abstract Number: 390 • 2014 ACR/ARHP Annual Meeting
Prevalence and Correlates of Patient-Physician Discordance in Early Rheumatoid Arthritis
John M. Davis III¹, Cynthia S. Crowson², Tim Bongartz¹, Clement J. Michet¹, Eric L. Matteson¹ and Sherine E. Gabriel³, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic, Rochester, MN, ³Health Sciences Research & Div of Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose Patients with rheumatoid arthritis (RA) sometimes rate their global disease activity differently than their rheumatologists. Previous studies describing this ‘discordance’ have primarily included patients…
Abstract Number: 389 • 2014 ACR/ARHP Annual Meeting
High 11B-HSD1 Activity Is Associated with Progression to Rheumatoid Arthritis in Patients with a New Onset of Inflammatory Arthritis
Dominika Nanus¹, Andrew Filer², Lorraine Yeo¹, Dagmar Scheel-Toellner³, Rowan Hardy⁴, Gareth Lavery⁵, Paul Stewart⁶, Christopher Buckley⁷, Mark Cooper⁸ and Karim Raza¹, ¹Rheumatology Research Group, University of Birmingham, Birmingham, United Kingdom, ²Rheumatology Research Group, MRC Centre for Immune Regulation, School of Immunity and Infection, University of Birmingham, Birmingham, United Kingdom, ³Rheumatology Research Group, Centre for Translational Inflammation Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, UK, Birmingham, United Kingdom, ⁴Centre for Endocrinology, Diabetes and Metabolism, University of Birmingham, Birmingham, United Kingdom, ⁵Centre for Endocrinology, Diabetes and Metabolism,, University of Birmingham, Birmingham, United Kingdom, ⁶University of Leeds, Leeds, United Kingdom, ⁷Rheumathology Research Group, University of Birmingham, Birmingham, United Kingdom, ⁸University of Sydney, ANZAC Research Institute, Sydney, Australia
Background/Purpose Inadequate endogenous glucocorticoid (GC) synthesis during inflammation has been proposed as an aetiological factor in the development of rheumatoid arthritis (RA). It has been…
Abstract Number: 388 • 2014 ACR/ARHP Annual Meeting
Soluble TREM-1 Is a Biomarker of Anti-CCP-Positive, DMARD-Naive Early Rheumatoid Arthritis
Shachaf Ofer-Shiber¹, Elisheva Pokroy-Shapira², Yair Molad^3,4, Shirly Oren², Hagit Shay-Aharoni² and Ilan Babai⁵, ¹Department of Internal Medicine H, Rabin Medical Center, Beilinson Hospital and Sackler Faculty of Medicine, Tel Aviv University, Petach Tikva, Israel, ²Rheumatology Unit, Rabin Medical Center, Beilinson Hospital and Sackler Faculty of Medicine, Tel Aviv University, Petach Tikva, Israel, ³Rheumatology Unit, Rabin Medical Center, Beilinson Hospital and Sackler Faculty of Medicine, Tel Aviv University, Petah Teqva, Israel, ⁴Laboratory of Inflammation Research, Felsenstein Medical Research Center, Sackler Faculty of Medicine, Tel Aviv University, Petach Tikva, Israel, ⁵Laboratory of Clinical Immunology, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel
Background/Purpose : Triggering receptor expressed on myeloid cells-1 (TREM-1) is a cell-surface receptor, expressed mainly on monocytes and neutrophils and involved in amplification of the inflammatory…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].